|Articles|June 1, 2001

June 2001
Volume 7
Issue 6

Effect of Rofecoxib Therapy on Measures of Health-Related Quality of Life in Patients with Osteoarthritis

Author(s)Elliott W. Ehrich, MD, James A. Bolognese, Mstat, Douglas J. Watson, PhD

Download PDF: Effect of Rofecoxib Therapy on Measures of Health-Related Quality of Life in Patients with Osteoarthritis

Articles in this issue

about 25 years ago

Article

Health Plan's Use of Asthma Quality Improvement Projects to Meet NCQA Accreditation Standards

about 25 years ago

Article

Does the HEDIS Asthma Measure Go Far Enough?

about 25 years ago

Article

Diagnosis and Care of Irritable Bowel Syndrome in a Community-Based Population

about 25 years ago

Article

Prevalence and Determinants of Osteoporosis Drug Prescription Among Patients with High Exposure to Glucocorticoid Drugs

about 25 years ago

Article

Rheumatoid Arthritis: Guidelines for Emerging Therapies

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Effect of Rofecoxib Therapy on Measures of Health-Related Quality of Life in Patients with Osteoarthritis

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Effect of Rofecoxib Therapy on Measures of Health-Related Quality of Life in Patients with Osteoarthritis

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment